In the field of bioprocess research and development, precise parameter control and reproducibility are key. Another important factor for economic efficiency of a lab is an effective use of lab space. The DASbox Mini Bioreactor System combines these requirements and more with smart software solutions, parallel bioprocessing option, as well as bioreactor and application flexibility. With this concept, the DASbox Mini Bioreactor System enables you to deliver big results at small scale.
New CCO starts in June
AppointmentsMarc Clausse will take up his new role as Chief Commercial Officer at Santhera Pharmaceuticals (SIX: SANN) at the beginning of June. He succeeds Geert Jan van Daal, who is retiring.
Harbour posts preclinical data on would-be rival to Eli Lilly’s $1.9B obesity bet
Latest NewsHarbour BioMed has published preclinical obesity data on a potential challenger to Eli Lilly’s bimagrumab discovered using its artificial intelligence-enabled platform.
Co-founder and CEO steps down
AppointmentsDr Andrea Pfeifer, long-serving CEO and co-founder from AC Immune, has decided to retire. AC Immune’s Board of Directors has appointed the Chair, Dr Martin Zügel, to serve as interim CEO while the ongoing search for a permanent successor continues.
$55m financing round for NVision
Latest NewsWith $55m in fresh capital, Ulm-based NVision is expanding its quantum technology platform from MRI sensing into quantum computing for drug development. The diagnostics company Abbott is the round’s anchor investor.
Millions for Preclinical Immunology: Boehringer Teams Up with Immunitas
Latest NewsGerman Boehringer Ingelheim is doubling down on next-generation autoimmune therapies with a deal worth up to €407.5m for a preclinical Immunitas (USA) antibody programme. The agreement highlights the growing race for selective immune-cell depletion approaches — and adds another strategic win for Novartis-, Merck-, Bayer- and Evotec-backed Immunitas.
Isomorphic Labs raises $2.1B for AI-enabled drug discovery drive
Latest NewsIsomorphic Labs has raised $2.1 billion (€1.8 billion) to further develop its artificial intelligence engine and advance drugs discovered using the platform.
Infex raises £4.3M for anti-infective R&D ahead of Phase 2a data on lead asset
Latest NewsInfex Therapeutics has raised £4.3 million (€4.95 million) to advance an anti-infective pipeline led by a midphase drug candidate.
EktaH links novel obesity drug to fat loss, muscle retention in early-phase trial
Latest NewsEktaH has shared early clinical trial data on its first-in-class approach to treating obesity, encouraging the biotech to aim to advance the program into Phase 2 in the first half of next year.
Tolemy Bio raises €1.4m to build AI control panel for cell biology
Latest NewsCambridge-based Tolemy Bio has raised €1.4m in pre-seed financing to develop Orbit, an AI-native platform designed to help biopharma teams interpret, optimise and control cell-based therapeutic processes.
The DASbox® Mini Bioreactor System: Small scale. Big results
ProductsIn the field of bioprocess research and development, precise parameter control and reproducibility are key. Another important factor for economic efficiency of a lab is an effective use of lab space. The DASbox Mini Bioreactor System combines these requirements and more with smart software solutions, parallel bioprocessing option, as well as bioreactor and application flexibility. With this concept, the DASbox Mini Bioreactor System enables you to deliver big results at small scale.